Epizyme Files for IPO, Aims for $69M for Epigenetics Platform

Epizyme Inc., the latest biotech to take advantage of the emerging growth company provision in last year's JOBS Act, filed an S-1 Friday for a proposed $69 million initial public offering (IPO), though the number of shares and share price have not yet been disclosed.